ND108E, the novel neurodegenerative disease drug developed by Holy Stone Healthcare Co., Ltd., has taken a significant step in the fight against Alzheimer's disease (AD). The potential of ND108E to restore cognitive function and memory in postmenopausal women was published in the October 25, 2023 edition of the "International Journal of Molecular Sciences". read more
Holy Stone Healthcare Co., Ltd. a new drug pharmaceutical company, participated in the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in Boston, USA, where the advancements of the self-developed Alzheimer’s Disease new drug ND108E was presented. read more
CA102N is an innovative investigational anticancer drug designed for the treatment of solid tumors, including colorectal cancer. CA102N is a carrier-mediated drug delivery product with hyaluronic acid (HA) conjugated to Nimesulide. The Hyaluronic Acid – Drug Conjugation (HADC) platform is specifically engineered to target the CD44 receptor overexpressed in solid tumors. HSHC has secured the patent protection of its HADC platform.
CA102N is a unique drug that inhibits tumor progression by inducing apoptosis and cell cycle arrest, and inhibiting metastasis and angiogenesis via targeting various signaling pathways such as the AKT pathway (PI3K/AKT/mTOR) pathway and promoting immune response. In addition, due to its direct tumor-targeting property via HA/CD44, an increase in drug accumulation at the target tumor site is observed, in vitro.
CA102N, as monotherapy or in combination with LONSURF, was shown to be safe and well-tolerated in subjects with locally advanced or metastatic solid tumors and/or colorectal cancer in a phase I study which implies that the treatment may have potential as part of a combination therapy approach to target cancer more effectively. Further preliminary evidence of anti-tumor activity was also observed in solid tumors, a positive indication that the CA102N treatment might have therapeutic benefits in treating cancer. Exploratory analysis in the dose expansion cohort revealed a favorable median progression-free survival. HSHC is responsible for the ongoing research, development, commercialization, and manufacturing of CA102N. read more